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results are reported over a one-year period after reaching steady-
state level of vaccination. Multiple probabilistic sensitivity analy-
sis was performed to estimate the distribution of the cost
difference between the two vaccines by running 5000 iterations
with @Risk(r) software in Excel(r) (normal distributions for
vaccine efﬁcacy, uniform distributions for HPV typing and costs).
RESULTS: Multiple probabilistic sensitivity analysis showed
an average annual cost difference of $9.3M (CDN) (95% CI:
-$10M, +$43M) in favor of cross-protection over genital warts
protection. Cross-protection provided additional cost saving
with an 86.3% probability. An efﬁcacy for additional cross
protection of around 12% would achieve cost neutrality. The
difference in cost was most sensitive to vaccine efﬁcacy of cross-
protection, the proportion of non-vaccine oncogenic HPV-types
in CIN1, and the unit cost of treating CIN1. CONCLUSION: A
vaccine with additional cross-protection of at least 12% is likely
to offset the costs associated with the protection against genital
warts in the Canadian health care system.
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COST DIVERSITY OF DRG BASED COLORECTAL CANCER
THERAPIES IN HUNGARY
Jozsa G
University of West Hungary, Sopron, Hungary
OBJECTIVE: In Hungary, costs of anti-cancer treatments are
covered by hospitals’ budget, and funds for therapy expenditures
provided from the National Health Fund Administration, based
on DRG accounts. The goal was to investigate the real cost of
treatments, and assess a comparison ofDRGbased remittance and
expenditures of therapies. METHODS: Cost analysis of CRC
chemotherapy-protocols has been conducted from the perspective
of Oncology Departments. Regimens of 5-ﬂuorouracil+/
-leukovorin, irinotecan, cetuximab, bevacizumab and oxali-
platin have been investigated, focusing on cost of medication,
hospitalisation and total expenditure of protocols. RESULTS:
Real expenditures of protocols were assessed. The range of drug
related costs were USD$18.20–3085.80 as expenditures of hospi-
tals. Total expenditures of chemotherapy-regimens have been
assessed and compared to allocation of remittances from the
National Health Fund Administration. The value of remittances
have been found between USD$405.70 and USD$2875.20,
depending on protocols. The gap analysis of drug expenditures
and remittances has resulted in a wide range of USD$-347 to
USD$1611. The ratio of drug related expenditures and total
remittance of hospitals showed diversity from 5% to 107%.
CONCLUSION: The analysis showed that ﬁxed DRG values had
not represented real expenditures of chemotherapies of CRC
treatment. Remittances should have been validated regularly.
Neither priority, nor incentive elements, have been found in
protocols containingmoleculeswith superior efﬁcacy or improved
safety. In general, Oncology Departments are motivated to use
protocols, containing generic compounds with low expenditures
and to achieve signiﬁcant savings in hospitals’ budget.
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A COST-EFFECTIVENESS ANALYSIS OF LAPATINIB AT A
TERTIARY CANCER CENTER
Lal LS,Arbuckle R
University of Texas MD Anderson Cancer Center, Houston,TX, USA
OBJECTIVE: As new agents become available for the treatment
of diseases, there exists a need to evaluate the cost-effectiveness
of the agents. This study calculates the cost-per life-year saved
and the budget impact of lapatinib, a new dual tyrosine inhibi-
tor as part of the formulary evaluation process at a major ter-
tiary cancer center. METHODS: A decision analytical model
was developed to estimate the incremental cost-effectiveness of
lapatinib for advanced breast cancer. The model estimates the
incremental cost-effectiveness of two strategies: combination
therapy of lapatinib with capecitabine compared to capecitabine
alone. The outcome of interest was time to disease progression,
based on randomized clinical trials (RCTs). Direct medical costs
from the institutional perspective were utilized and were calcu-
lated for a one year time period. One-way and two-way sensi-
tivity analysis on the rate of disease progression for
monotherapy and combination therapy was conducted. In addi-
tion, a budget impact model was also calculated for the insti-
tution. RESULTS: Based on outcome estimates from RCTs and
the application of the institutional costs, the cost-per-life-year
saved for lapatinib for treatment of advanced breast cancer was
$108,300. One-way sensitivity analysis of the combination
response (0–50%) indicated that lapatinib’s cost-effectiveness
ratios ranged from $100,000 to $119,000 per life-year saved.
Two-way sensitivity analysis indicated that the majority of the
time monotherapy was more cost-effective. The lapatinib com-
bination was only considered cost-effective, if the response rate
of the monotherapy never exceeded 14.6%. The budget impact
model, which incorporated both on-label and off-label usage of
lapatinib, estimated that the institution will utilize about 10
million dollars worth of drugs annually, based on acquisition
costs. CONCLUSION: Lapatinib appears to have similar cost-
effectiveness in comparison with other targeted oncology agents.
Post evaluation economic analysis will be conducted to deter-
mine how closely the economic model predicted the utilization
of lipatinib at the institution.
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OBJECTIVE: Patients with chronic lymphocytic leukemia (CLL)
are often treated with prophylactic intravenous immunoglobulin
(IVIG) to reduce risk of infection, although increased survival has
not been demonstrated with use. The objective of this study was
to estimate direct medical costs of IVIG versus no prophylaxis
over 12 months. METHODS: Costs were estimated from the
government (Medicare) perspective when available, or calculated
from the literature in 2007 US dollars. Assuming a regimen of
400mg/kg every four weeks for one year, 12 administrations for
a 70kg patient was calculated using a reimbursement of $30 per
500mgs. Estimated resources costs were $24 per preparation and
$144 per administration. Infections were considered minor, mod-
erate, or severe and both costs and probabilities of infection were
extracted from previous studies. Risk of any infection with IVIG
use was 36% and with no prophylaxis, 56%. Reported infections
per year among patients with 1+ infection was 1.4 with IVIG use
and 2.25 infections with no prophylaxis. RESULTS: Under
the described model, the total cost per year of prophylactic
IVIG = $24,512 per patient. The weighted average cost per infec-
tion was $1688. The average weighted infection cost (AWIC)
of minor infections = $12; moderate, AWIC = $96; and severe,
AWIC = $2256. In comparison, total cost with no prophylaxis
was $4500 per patient year. The weighted average cost of one
infection with no prophylaxis = $2000. The AWIC of minor
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infections in untreated patients = $31; moderate, AWIC = $287;
and severe, AWIC = $4182. CONCLUSION: These data show
IVIG prophylaxis cost $24,512 per patient year, compared to
$4500 with no prophylaxis, or about a 445% increase in cost.
The cost-effectiveness of IVIG in CLL has not been established,
and availability of IVIG is limited. Further studies on other
alternatives, such as prophylactic antibiotic therapy, and impact
on quality of life are needed.
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OBJECTIVE: There have been numerous studies on cost-
effectiveness of trastuzumab in both treatments of adjuvant and
metastatic breast cancer (BC). Nevertheless, the results reported
were varied depending upon the assumptions and/or perspectives
of the studies. We performed a systematic review of cost-
effectiveness-analysis (CEA) studies of trastuzumab in treatment
of HER2-postive breast cancer. METHODS: Literature search
from 1996 to December 2007 on databases including PubMed,
Ovid MEDLINE, and HealthSTAR was performed to retrieve
CEA studies of trastuzumab, using MESH terms and keywords
such as “trastuzumab,” “costs and cost analysis,” “economics,”
“breast neoplasm,” “cost effectiveness,” “cost utility,” and
“breast cancer.” Additionally, abstracts on CEA studies were also
obtained from American Society of Clinical Oncology (ASCO)
and ISPOR annual meetings. Only CEA studies reported incre-
mental cost-effectiveness ratio (ICER) or cost-utility ratio (ICUR)
as cost per quality-adjusted life years were included in this
review. RESULTS: Thirty ﬁve studies (20 published articles and
15 abstracts) were identiﬁed, of which 18 studies (14 adjuvant, 3
metastatic BC studies, and 1 study of product life-cycle of tras-
tuzumab) representing societal health care perspectives from 12
countries were satisﬁed the criteria. The mean (median) ICERs of
trastuzumab are $24,069/QALY ($23,766/QALY) [ranged from
$4,767 to $58,414/QALY] and $88,373/QALY ($80,000/QALY)
[ranged from $60,120 to $125,000/QALY] for HER2-postive
adjuvant and metastatic breast cancer treatments, respectively.
Majority of sensitivity analyses showed the main cost driver was
the acquisition cost of trastuzumab. In addition, over the product
life-cycle of trastuzumab, the overall ICER is $34,400/QALY
(Garrison et al., 2006). CONCLUSION: This review suggests
that the average costs per QALY of trastuzumab in both treat-
ments of adjuvant and metastatic HER2-positive breast cancer
are consistent and below the suggested cost effectiveness thresh-
old of $100,000/QALY.
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Orchard MC1, Hoch J1,Alibhai SMH2
1University of Toronto,Toronto, ON, Canada, 2University Health
Network,Toronto, ON, Canada
OBJECTIVE: To explore the cost-effectiveness of capecitabine as
adjuvant treatment for Stage III colon cancer. Phase III clinical
trials show that capecitabine improves disease-free survival.
However, these trials involved younger patients than reﬂected
clinically and overall survival was not signiﬁcantly better than
with usual care. We conducted a modeling study comparing
the cost-effectiveness of capecitabine and standard care
(Fluorouracil/Leucovorin (5FU/LV)) in a public-payer context
(Canada), using an older cohort, and with overall survival as the
main outcome. METHODS: A Markov model was developed
to determine the cost-effectiveness of capecitabine compared
with 5FU/LV. The base case was a 70-year-old man after total
mesorectal resection excision of Stage III colon cancer. A ﬁve
year time horizon was used. Health states included treatment
phase, remission, recurrence, disease progression, and death;
throughout the model (except during the active treatment states)
patients could die from other risk-related causes. Ontario health
economic data were used for costs. Probabilities were obtained
from the published literature, and sensitivity analyses were con-
ducted. RESULTS: The base case costs for capecitabine and
5FU/LV were $12,999 and $12,191, respectively. Overall sur-
vival was 4.132 and 4.069 years, respectively. The incremental
cost-effectiveness ratio of capecitabine was $12,821 per life year
gained. However, the incremental cost-effectiveness ratio of
capecitabine was greater than $50,000/life year when the annual
probability of relapse was greater than 0.96 or when drug costs
were assumed to be greater than $1410 per cycle (both values
within the plausible range). CONCLUSION: Capecitabine pro-
duced modestly improved survival over 5FU/LV (0.063 extra
years) with a favourable cost-effectiveness ratio. However,
because the model was sensitive to variations in relapse rate and
drug costs, the relative attractiveness of capecitabine over
5FU/LV is not certain. In addition, utilities and indirect costs
were not considered in the model. Because capecitabine is
administered orally, this could be an important factor warrant-
ing further research.
PCN23
COST-EFFECTIVENESS ANALYSIS OF LAPATINIB PLUS
CAPECITABINEVERSUS CAPECITABINE ALONE IN
THE SECOND LINETREATMENT FOR BREAST
CANCERTREATMENT
Ejzykowicz F, Hay JW
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: Compare two therapy regimens, Lapatinib plus
Capecitabine to Capecitabine alone, for advanced or Metastatic
HER2-positive breast cancer patients who were pretreated with
regimens that included an anthracycline, a taxane, and trastu-
zumab. METHODS: A Markov model, written in Microsoft
Excel(r), is used to simulate progression of breast cancer in a
hypothetical cohort of breast cancer patients in a societal per-
spective. The model consists of three health states: Clinical
Beneﬁts (Response or Stable Disease), Progressive Disease, and
Death. Transitions between health states were assumed to occur
once a month. Life expectancy, costs and QALYs are discounted
monthly by 0.0025% (3% annually). All costs are adjusted to
2007 dollars. RESULTS: Lapatinib plus Capecitabine increases
discounted life expectancy and quality-adjusted life expectancy
by 0.43 years and 0.54 years, respectively, when compared
to Capecitabine alone. This result yields an incremental cost-
effectiveness ratio (ICER) of USD$135,701.69 per QALY (upper
95% CI USD$230,864.99 per QALY), which may be cost effec-
tive, based on the threshold of USD$150,000/QALY. If the value
of Lapatinib price increases at least 13.4%, the combination
therapy is no longer cost-effective. The same outcome is observed
if we increase the transition probability from the Clinical Beneﬁts
state to the Progressive Disease state in the combination therapy
by 12.5% or if we decrease it by 19.3% in monotherapy.
Additionally, by using the 5th percentile of the utility for
Clinical Beneﬁts and the 95th percentile of the utility for
Progressive Disease, the ICER is US$D281,091.34/QALY and
USD$201,232.58/QALY, respectively. CONCLUSION: Based on
a threshold of USD$150,000/QALYs, the treatment with Lapa-
tinib plus Capecitabine is cost-effective in the base case for
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